The Board proposes share issue

[REMOVED GRAPHICS] PRESS RELEASE The BioPhausia Board proposes the Annual General Meeting to authorize the Board to decide on a new share issue The Board of Directors of BioPhausia AB (publ) proposes to the Annual General Meeting on April 26 1999 to authorize the Board to decide on a new issue of Series A and/or Series B shares, whereby the issue may be effected without regard to shareholders´ preferential rights. The shares thus issued may result in a total increase in share capital of not more than SEK 25,000,000 (10,000,000 shares at a par value of SEK 2.50 each). Johannes Norrby, Chairman of the Board of Directors, issued the following statement: "BioPhausia needs a capital contribution, approximately 50 MSEK, primarily in order to promote the projects within tumour and trauma treatment areas, secondly to bridge the time until RescueFlow® and Krillase® will generate royalty and similar license revenues. The proposal to authorize the Board to decide on a share issue will increase the number of alternatives for the Board." Uppsala, April 6, 1999 Based on its contact network and know-how, primarily in connective tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The product and project portfolio includes RescueFlow®, a resuscitation solution, Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. For additional information, please call: Johannes Norrby, Chairman of the Board, phone: +46 (0)70-606 24 97 ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/04/12/19990412BIT00530/bit0001.doc http://www.bit.se/bitonline/1999/04/12/19990412BIT00530/bit0002.pdf